JP5296701B2 - 線維性疾患および線維増殖性疾患を処置および診断するための方法 - Google Patents

線維性疾患および線維増殖性疾患を処置および診断するための方法 Download PDF

Info

Publication number
JP5296701B2
JP5296701B2 JP2009539524A JP2009539524A JP5296701B2 JP 5296701 B2 JP5296701 B2 JP 5296701B2 JP 2009539524 A JP2009539524 A JP 2009539524A JP 2009539524 A JP2009539524 A JP 2009539524A JP 5296701 B2 JP5296701 B2 JP 5296701B2
Authority
JP
Japan
Prior art keywords
subject
circulating
disease
fibroblasts
fibrotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009539524A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010511389A5 (https=
JP2010511389A (ja
Inventor
ボーナ・メーラッド
マリー・ディ・バーディック
デイビッド・エイ・ジスマン
マイケル・ピー・キーン
ジョン・エイ・ベルペリオ
ロバート・エム・ストリーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Los Angeles UCLA
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2010511389A publication Critical patent/JP2010511389A/ja
Publication of JP2010511389A5 publication Critical patent/JP2010511389A5/ja
Application granted granted Critical
Publication of JP5296701B2 publication Critical patent/JP5296701B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009539524A 2006-11-30 2007-11-30 線維性疾患および線維増殖性疾患を処置および診断するための方法 Expired - Fee Related JP5296701B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87201906P 2006-11-30 2006-11-30
US60/872,019 2006-11-30
PCT/US2007/086167 WO2008067559A2 (en) 2006-11-30 2007-11-30 Methods for treating and diagnosing fibrotic and fibroproliferative diseases

Publications (3)

Publication Number Publication Date
JP2010511389A JP2010511389A (ja) 2010-04-15
JP2010511389A5 JP2010511389A5 (https=) 2011-01-20
JP5296701B2 true JP5296701B2 (ja) 2013-09-25

Family

ID=39468768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009539524A Expired - Fee Related JP5296701B2 (ja) 2006-11-30 2007-11-30 線維性疾患および線維増殖性疾患を処置および診断するための方法

Country Status (5)

Country Link
US (2) US8114608B2 (https=)
EP (1) EP2100140B1 (https=)
JP (1) JP5296701B2 (https=)
AU (1) AU2007325029B2 (https=)
WO (1) WO2008067559A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101466931B1 (ko) 2006-07-18 2014-12-02 녹손 파르마 아게 Sdf-1 결합형 b형 핵산분자
US8772257B2 (en) * 2007-08-06 2014-07-08 Noxxon Pharma Ag SDF-1 binding nucleic acids and the use thereof
JP2012506558A (ja) * 2008-10-22 2012-03-15 アローキュア インコーポレイテッド 腎損傷および他の主要な器官を処置するための、診断用および間葉系幹細胞（多能性間質細胞）特異的な治療用のバイオマーカーとしてのｓｄｆ−１（ｃｘｃｌ１２）を使用する方法
JP2012127879A (ja) * 2010-12-16 2012-07-05 Kanazawa Univ 腎症の進行度の判定方法並びに線維化抑制剤。
CN103376228B (zh) * 2012-04-27 2016-02-17 中国人民解放军军事医学科学院放射与辐射医学研究所 一种检测或辅助检测放射性肺纤维化的试剂盒
WO2014139884A2 (en) * 2013-03-14 2014-09-18 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrosis
JP6601707B2 (ja) * 2015-02-15 2019-11-06 国立大学法人金沢大学 線維化判定方法
JP7126668B2 (ja) * 2017-08-09 2022-08-29 国立大学法人金沢大学 膠原病判定方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759036B1 (en) * 1997-03-28 2004-07-06 The Picower Institute For Medical Research Fibrocyte-base vaccine formulations
US8293479B2 (en) * 2002-05-02 2012-10-23 Los Angeles Biomedical Research Institute At Harbor Ucla Medical Center Use of parathyroid hormone-related protein(PTHRP) in the diagnosis and treatment of chronic lung disease and other pathologies
PT1596880E (pt) * 2002-12-23 2011-06-06 Univ Rice William M Métodos e composições para suprimir a diferenciação de fibrócitos

Also Published As

Publication number Publication date
US20120094305A1 (en) 2012-04-19
EP2100140B1 (en) 2015-05-06
US20100074887A1 (en) 2010-03-25
US8114608B2 (en) 2012-02-14
EP2100140A4 (en) 2010-07-21
EP2100140A2 (en) 2009-09-16
WO2008067559A2 (en) 2008-06-05
JP2010511389A (ja) 2010-04-15
AU2007325029B2 (en) 2013-09-12
AU2007325029A1 (en) 2008-06-05
US8216796B2 (en) 2012-07-10
WO2008067559A3 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
JP5296701B2 (ja) 線維性疾患および線維増殖性疾患を処置および診断するための方法
Chen et al. Leukocyte cell‐derived chemotaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitment
US9359402B2 (en) EphA2 T-cell epitope agonists and uses therefore
US9399675B2 (en) Methods and compositions for diagnosing Alzheimer's disease and age-related macular degeneration
Chen et al. The significance of titin antibodies in myasthenia gravis: correlation with thymoma and severity of myasthenia gravis
US20180280503A1 (en) Anti-pad2 antibody for treating and evaluating rheumatoid arthritis
WO2011157905A1 (en) Polyclonal antibody binding to acetylated hmgb1
EP2577297A2 (en) Methods of diagnosing asthma
Bruneau et al. Potential role of soluble ST2 protein in idiopathic nephrotic syndrome recurrence following kidney transplantation
WO2013107826A2 (en) Use of cellular biomarkers expression to diagnose sepsis among intensive care patients
US20100297147A1 (en) Compositions and methods for modulating tlr14 activity
US9945843B2 (en) Methods for identifying compounds that inhibit G protein-coupled receptor (GPR84) agonist-stimulated chemotaxis
Bonner et al. Expression of functional receptor activity modifying protein 1 by airway epithelial cells with dysregulation in asthma
US20200132673A1 (en) Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
US7838490B2 (en) Methods and compositions for inhibition of vascular permeability
US20130065825A1 (en) Compositions and Methods for Delaying Senescence or Cell Death in Neurons
KR20140109956A (ko) 테나신-c 및 류마티스 관절염에서의 이의 용도
EP4726391A1 (en) Novel citrullinated peptides that bind to anti-citrullinated protein antibodies (acpas) and their use in the diagnosis and prediction of rheumatoid arthritis
JP2004000209A (ja) 軟骨障害マーカー及びその利用
Dong Investigation of TSG-6 as a Potential Biomarker and Therapeutic Target in Osteoarthritis
KR20080085923A (ko) 백혈구 기능 저해를 위한 조성물 및 방법
Class et al. Patent application title: SCREENING METHODS TO IDENTIFY COMPOUNDS USEFUL IN THE PREVENTION AND/OR TREATMENT OF INFLAMMATORY CONDITIONS Inventors: Reginald Christophe Xavier Brys (Mechelen, BE) Reginald Christophe Xavier Brys (Mechelen, BE) Sonia Dupont (Romainville, FR) Assignees: GALAPAGOS NV
Østergaard et al. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987
HK40016117A (en) A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction
WO2007042778A2 (en) Monitoring cardiovascular disease by determining the expression of kir2ds2 and/or dap12

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130521

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130613

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5296701

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees